Prescribing information


Prescribing information



Click here for ILARIS® (canakinumab) prescribing information.

Speakers: Prof. Dr Jasmin Kümmerle-Deschner, Division of Paediatric Rheumatology, Department of Paediatrics and Autoinflammation Reference Centre, University Hospital Tübingen, Germany.

Prof. Dr Maria Cristina Maggio, Dipartimento PROMISE G. D’Alessandro Università degli Studi di Palermo, Ospedale dei Bambini, ARNAS, Palermo. 

The Paediatric Rheumatology Congress (PReS) webinar is in two parts. Firstly, Paediatric Rheumatologist Prof. Dr Jasmin Kümmerle-Deschner discusses a case study of a young patient with familial Mediterranean fever (FMF), his treatment goals and targeting disease control through interleukin-1 (IL-1) inhibition. Secondly, Paediatric Rheumatologist Prof. Dr Maria Cristina Maggio explores the key principles in the management of patients with FMF, with a specific focus on improving quality of life and patient engagement.

Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:1

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

Still's disease
ILARIS is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. ILARIS can be given as monotherapy or in combination with methotrexate.1

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS/MKD, hyperimmunoglobulin D syndrome mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.


  1. ILARIS® (canakinumab) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | May 2022 | 200191

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]